Literature DB >> 2833574

Loss of cortical GABA uptake sites in Alzheimer's disease.

M D Simpson1, A J Cross, P Slater, J F Deakin.   

Abstract

[3H]Nipecotic acid bound to membranes of human brain in a saturable, reversible manner which was totally dependent on the presence of sodium ions. The potencies of compounds in inhibiting the specific binding of [3H]nipecotic acid were closely correlated with their potencies in inhibiting the neuronal uptake of [3H]GABA. Compounds selective for GABA receptors were inactive. [3H]Nipecotic acid appears to label neuronal high affinity GABA uptake sites. The binding of [3H]nipecotic acid was substantially reduced in the temporal cortex of brains from subjects with Alzheimer-type dementia, but not in other brain regions. It is concluded that some loss of GABA terminals occurs in this disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833574     DOI: 10.1007/BF01245715

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  33 in total

1.  Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.

Authors:  P L McGeer; E G McGeer
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

2.  Evaluation of a semiautomatic filtration technique for receptor binding studies.

Authors:  H Hall; L Thor
Journal:  Life Sci       Date:  1979-06-11       Impact factor: 5.037

3.  Uptake of [14C]nipecotic acid into rat dorsal root ganglia.

Authors:  M C Minchin
Journal:  J Neurochem       Date:  1979-05       Impact factor: 5.372

4.  Sodium-dependent binding of GABA to mouse brain particles.

Authors:  E Roberts; E Wong; G Svenneby; P Degener
Journal:  Brain Res       Date:  1978-09-08       Impact factor: 3.252

5.  Lowry method of protein quantification: evidence for photosensitivity.

Authors:  J M Dawson; P L Heatlie
Journal:  Anal Biochem       Date:  1984-08-01       Impact factor: 3.365

6.  The selective neuronal uptake and release of [3H]DL-2,4-diaminobutyric acid by rat cerebral cortex.

Authors:  F Weitsch-Dick; T M Jessell; J S Kelly
Journal:  J Neurochem       Date:  1978-04       Impact factor: 5.372

7.  Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type.

Authors:  P Davies; R D Terry
Journal:  Neurobiol Aging       Date:  1981       Impact factor: 4.673

8.  Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia.

Authors:  C Q Mountjoy; M N Rossor; L L Iversen; M Roth
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

9.  Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects.

Authors:  E G Spokes; N J Garrett; M N Rossor; L L Iversen
Journal:  J Neurol Sci       Date:  1980-12       Impact factor: 3.181

10.  A disorder of cortical GABAergic innervation in Alzheimer's disease.

Authors:  J Hardy; R Cowburn; A Barton; G Reynolds; P Dodd; P Wester; A M O'Carroll; E Lofdahl; B Winblad
Journal:  Neurosci Lett       Date:  1987-01-14       Impact factor: 3.046

View more
  8 in total

1.  High-affinity transport of choline and amino acid neurotransmitters in synaptosomes from brain regions after lesioning the nucleus basalis magnocellularis of young and aged rats.

Authors:  J Gomeza; C Aragón; C Giménez
Journal:  Neurochem Res       Date:  1992-04       Impact factor: 3.996

2.  Neuropharmacological correction of cognitive processes disrupted by extirpation of the AI-AII and Ep fields in cats.

Authors:  E I Mukhin
Journal:  Neurosci Behav Physiol       Date:  1996 Nov-Dec

3.  Region specific regulation of glutamic acid decarboxylase mRNA expression by dopamine neurons in rat brain.

Authors:  N Lindefors; S Brene; M Herrera-Marschitz; H Persson
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  Glutamate and GABA-metabolizing enzymes in post-mortem cerebellum in Alzheimer's disease: phosphate-activated glutaminase and glutamic acid decarboxylase.

Authors:  G Sh Burbaeva; I S Boksha; E B Tereshkina; O K Savushkina; T A Prokhorova; E A Vorobyeva
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

Review 5.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

Review 6.  Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.

Authors:  Karan Govindpani; Beatriz Calvo-Flores Guzmán; Chitra Vinnakota; Henry J Waldvogel; Richard L Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2017-08-21       Impact factor: 5.923

Review 7.  Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease.

Authors:  Grzegorz A Czapski; Joanna B Strosznajder
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

8.  Impaired Expression of GABA Signaling Components in the Alzheimer's Disease Middle Temporal Gyrus.

Authors:  Karan Govindpani; Clinton Turner; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.